News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
39,841 Results
Type
Article (2567)
Company Profile (40)
Press Release (37234)
Section
Business (14596)
Career Advice (81)
Deals (2174)
Drug Delivery (9)
Drug Development (4323)
Employer Resources (10)
FDA (494)
Job Trends (870)
News (21003)
Policy (1145)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (148)
Allergies (4)
Alliances (3557)
ALS (4)
Alzheimer's disease (47)
Antibody-drug conjugate (ADC) (14)
Approvals (497)
Artificial intelligence (9)
Autoimmune disease (2)
Automation (1)
Bankruptcy (13)
Best Places to Work (585)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (18)
Cancer (131)
Cardiovascular disease (5)
Career advice (68)
Career pathing (1)
CAR-T (14)
Cell therapy (42)
Cervical cancer (3)
Clinical research (3346)
Collaboration (90)
Compensation (43)
COVID-19 (196)
CRISPR (7)
C-suite (25)
Cystic fibrosis (2)
Data (111)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (476)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4454)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6254)
Executive appointments (86)
FDA (537)
Featured Employer (4)
Funding (75)
Gene editing (14)
Gene therapy (17)
GLP-1 (61)
Government (165)
Healthcare (775)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (15)
Indications (2)
Infectious disease (203)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (8)
IPO (1025)
IRA (7)
Job creations (298)
Job search strategy (65)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (226)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (19)
MASH (4)
Medical device (338)
Medtech (338)
Mergers & acquisitions (1212)
Metabolic disorders (33)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (89)
NextGen: Class of 2025 (366)
Non-profit (176)
Northern California (340)
Now hiring (4)
Obesity (15)
Opinion (16)
Ovarian cancer (10)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (19)
Patient recruitment (2)
Peanut (1)
People (5757)
Pharmaceutical (6)
Phase I (1426)
Phase II (1667)
Phase III (918)
Pipeline (66)
Podcasts (5)
Policy (11)
Postmarket research (35)
Preclinical (607)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (21)
Real estate (431)
Recruiting (5)
Regulatory (874)
Reports (6)
Research institute (152)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (331)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (498)
Stomach cancer (1)
Supply chain (4)
The Weekly (2)
United States (1653)
Vaccines (56)
Venture capitalists (7)
Webinars (2)
Weight loss (11)
Women's health (1)
Worklife (1)
Date
Today (15)
Last 7 days (55)
Last 30 days (214)
Last 365 days (2652)
2025 (624)
2024 (2722)
2023 (3036)
2022 (3918)
2021 (4242)
2020 (3612)
2019 (2188)
2018 (1617)
2017 (1883)
2016 (1689)
2015 (1937)
2014 (1426)
2013 (1253)
2012 (1472)
2011 (1418)
2010 (1233)
Location
Africa (46)
Alabama (1)
Arizona (14)
Asia (1956)
Australia (309)
California (777)
Canada (131)
China (37)
Colorado (20)
Connecticut (10)
Delaware (4)
Europe (4146)
Florida (43)
Georgia (5)
Idaho (3)
Illinois (15)
India (1)
Indiana (30)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (278)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (2)
New Jersey (78)
New York (55)
North Carolina (88)
North Dakota (1)
Northern California (340)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (47)
Rhode Island (2)
South America (43)
South Carolina (1)
Southern California (331)
Tennessee (2)
Texas (67)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (44)
Wisconsin (6)
39,841 Results for "valent biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Valent BioSciences Opens New State-of-the-Art Addition at Melnik and Shafer Biorational Research Center
Valent BioSciences celebrated the grand opening of the new Venburg Wing at the company’s Melnik and Shafer Biorational Research Center in Libertyville, Illinois, during a special ceremony.
May 29, 2024
·
3 min read
BioMidwest
Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions Space
Sumitomo Chemical Co., Ltd. and Valent BioSciences LLC announced that Pace International LLC and its operations overseas will become part of AgroFresh Solutions, Inc., a well-established leader in the postharvest solutions space.
March 27, 2024
·
5 min read
Press Releases
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
March 27, 2025
·
14 min read
Press Releases
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
January 31, 2025
·
8 min read
BioMidwest
Valent BioSciences Hosts Sustainability Celebration at Osage Facility
Broadening its commitment to sustainability and corporate social value, Valent BioSciences LLC formally dedicated a new prairie park and solar field adjacent to its manufacturing facility in Osage, Iowa, on June 24.
June 26, 2023
·
4 min read
Drug Development
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410', evaluating its safety and immunogenicity.
June 29, 2023
·
4 min read
Deals
Valent BioSciences Announces the Acquisition of FBSciences
Valent BioSciences LLC announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions.
January 30, 2023
·
5 min read
Job Trends
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain.
April 29, 2024
·
12 min read
Business
Valent BioSciences Announces the Retirement of Ted Melnik and Promotion of Salman Mir
Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces the retirement of President and CEO Ted Melnik, effective July 2023.
April 24, 2023
·
4 min read
Press Releases
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 24, 2024
·
11 min read
1 of 3,985
Next